Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Fig. 1

Overall Survival in the overall population by volume of disease at AA/Enza start and time of metastatic disease presentation. AA abiraterone acetate plus prednisone, DN de-novo, Enza enzalutamide, CI confidence interval, HR hazard ratio, HV high volume, LV low volume, OS overall survival, PLT prior local therapy

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us